Julien Matricon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julien Matricon has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A. Gelot
Clermont Université Université d'Auvergne Institut Universitaire de Technologie Plateau Campus les Cézeaux Aubière France
1 shared publication- Alexandre Seillier
Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA
1 shared publication - Andrea Giuffrida
Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
1 shared publication D. Ardid
Clermont Université Université d'Auvergne Institut Universitaire de Technologie Plateau Campus les Cézeaux Aubière France
1 shared publicationE. Muller
Clermont Université Université d'Auvergne NEURO‐DOL Clermont‐Ferrand France
1 shared publicationM. Dapoigny
CHU Clermont‐Ferrand Hôtel Dieu Service d'Hépato‐Gastroentérologie Clermont‐Ferrand France
1 shared publication
Latest Publications
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S46
ENDOCANNABINOID-ENHANCING DRUGS REVERSE SOCIAL WITHDRAWAL IN THE PCP RAT MODEL OF SCHIZOPHRENIA
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S46
ENDOCANNABINOID-ENHANCING DRUGS REVERSE SOCIAL WITHDRAWAL IN THE PCP RAT MODEL OF SCHIZOPHRENIA
- 16 November 2012
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 36 (11-12) , 1009-1031
Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome
Summary: Background: Irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, markedly impairing patients' quality of life. Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology. In recent years, numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients.Aim: To determine whether immune activation and intestinal permeabilisation are more frequently observed in IBS patients compared with healthy controls.Methods: The scientific bibliography was searched using the following keywords: irritable bowel syndrome, inflammation, immune activation, permeabilisation, intestine, assay, histology and human. The retrieved studies, including blood, faecal and histological studies, were analysed to provide a comprehensive and structured overview of the available data including the type of assay, type of inflammatory marker investigated or intestinal segment studied.Results: Immune activation was more frequently observed in IBS patients than in healthy controls. An increase in the number of mast cells and lymphocytes, an alteration in cytokine levels and intestinal permeabilisation were reported in IBS patients. No consistent changes in the numbers of B cells or enterochromaffin cells or in mucosal serotonin production were demonstrated.Conclusions: The changes observed were modest and often heterogeneous among the studied population. Only appropriate interventions improving irritable bowel syndrome symptoms could highlight and confirm the role of immune activation in this pathophysiology.
- 16 November 2012
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 36 (11-12) , 1009-1031
Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome
Summary: Background: Irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, markedly impairing patients' quality of life. Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology. In recent years, numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients.Aim: To determine whether immune activation and intestinal permeabilisation are more frequently observed in IBS patients compared with healthy controls.Methods: The scientific bibliography was searched using the following keywords: irritable bowel syndrome, inflammation, immune activation, permeabilisation, intestine, assay, histology and human. The retrieved studies, including blood, faecal and histological studies, were analysed to provide a comprehensive and structured overview of the available data including the type of assay, type of inflammatory marker investigated or intestinal segment studied.Results: Immune activation was more frequently observed in IBS patients than in healthy controls. An increase in the number of mast cells and lymphocytes, an alteration in cytokine levels and intestinal permeabilisation were reported in IBS patients. No consistent changes in the numbers of B cells or enterochromaffin cells or in mucosal serotonin production were demonstrated.Conclusions: The changes observed were modest and often heterogeneous among the studied population. Only appropriate interventions improving irritable bowel syndrome symptoms could highlight and confirm the role of immune activation in this pathophysiology.